论文部分内容阅读
目的旨在探讨阿瑞匹坦对黑色素瘤患者顺铂治疗引起的恶心呕吐的作用。方法 170例接受含顺铂方案治疗的黑色素瘤患者,随机分入阿瑞匹坦组和对照组进行预防性止吐治疗。记录患者顺铂治疗后的恶心、呕吐反应,解救治疗,功能性生活指数(呕吐)及其他不良反应。结果两组中各84例患者可评价疗效。阿瑞匹坦组患者的完全缓解率(无呕吐,无解救治疗)为69%,显著高于对照组的44%(χ2=10.683,P=0.001)。阿瑞匹坦组和对照组的呕吐发生率分别为27%和51%,阿瑞匹坦组显著优于对照组(χ2=9.982,P=0.002)。阿瑞匹坦组未观察到相关的不良反应。结论阿瑞匹坦可显著降低黑色素瘤患者中顺铂引起的呕吐反应。尽管阿瑞匹坦的安全性良好,在给药前仍需注意药物间的相互作用。
Purpose To investigate the effect of aprepitant on nausea and vomiting induced by cisplatin in patients with melanoma. Methods A total of 170 patients with melanoma treated with cisplatin were randomly divided into aprepitant group and a control group for prophylactic antiemetic treatment. The nausea, vomiting, rescue treatment, functional life index (vomiting), and other adverse reactions were recorded after treatment with cisplatin. Results 84 patients in each group could evaluate the curative effect. The complete remission (no vomiting, no rescue) in the aprepitant group was 69%, significantly higher than the 44% in the control group (χ2 = 10.683, P = 0.001). The rates of emesis in the aprepitant group and the control group were 27% and 51%, respectively, and aprepitant group was significantly better than the control group (χ2 = 9.982, P = 0.002). No adverse reactions were observed in the aprepitant group. Conclusion Aprepitant can significantly reduce cisplatin-induced vomiting in patients with melanoma. Despite the safety of aprepitant, care needs to be taken before drug delivery.